Topline data were announced from a phase 3 trial evaluating CagriSema in overweight or obese patients without type 2 diabetes ...

“We are encouraged by the weight loss profile of CagriSema demonstrating superiority over both semaglutide and cagrilintide in monotherapy in the REDEFINE 1 trial,” said Martin Holst ...

These names in the biotech sector are seeing a substantial increase in search activity today, as determined by InvestingChannel. They ...

we plan to further explore the additional weight loss potential of CagriSema," said Martin Holst Lange, executive vice president for Development at Novo Nordisk. The company stated: "The results ...

Novo Nordisk shares have plunged 20% amid the disappointing trial result of its latest weight-loss drug CagriSema. The fall wiped out €90bn in market valuation on Friday.View on euronews ...

(CNN) — Since Ozempic blasted onto the stage in 2017 with its approval for type 2 diabetes, drugmakers Novo Nordisk and ... in monotherapy,” Martin Holst Lange, executive vice president ...

"This was achieved even though only 57% of patients reached the highest CagriSema dose," commented Martin Holst Lange, Novo Nordisk's executive vice president for Development. Lange highlighted the ...

Novo Nordisk shares fell sharply on Friday as disappointing results from tests of its latest obesity drug wiped about €90 billion off the valuation of Europe’s largest company by market ...

But Martin Holst Lange, Novo Nordisk's executive vice-president for development, said: 'We are encouraged by the weight-loss profile of CagriSema.' Some believe the market reaction was overdone.

The result fell short of the 25 per cent Novo Nordisk had expected for the drug, sending shares down over 22 per cent following the announcement.Martin Holst Lange, executive vice president for ...

“We are encouraged by the weight loss profile of CagriSema demonstrating superiority over both semaglutide and cagrilintide in monotherapy,” Martin Holst Lange, executive vice president for ...